Dianthus Therapeutics Inc.
$ 82.07
7.35%
12 Jun - close price
- Market Cap 4,486,458,000 USD
- Current Price $ 82.07
- High / Low $ 83.61 / 77.16
- Stock P/E N/A
- Book Value 22.01
- EPS -4.23
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.15 %
- ROE -0.23 %
- 52 Week High 96.50
- 52 Week Low 16.64
About
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
Analyst Target Price
$127.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-09 | 2025-11-05 | 2025-08-07 | 2025-05-12 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-03 |
| Reported EPS | -0.85 | -1.43 | -0.97 | -0.88 | -0.82 | -0.81 | -0.74 | -0.51 | -0.54 | -0.71 | -3.78 | -0.8663 |
| Estimated EPS | -1.1 | -1.0314 | -0.9 | -0.87 | -0.71 | -0.76 | -0.6 | -0.55 | -0.44 | -1.01 | -0.56 | -3.04 |
| Surprise | 0.25 | -0.3986 | -0.07 | -0.01 | -0.11 | -0.05 | -0.14 | 0.04 | -0.1 | 0.3 | -3.22 | 2.1737 |
| Surprise Percentage | 22.7273% | -38.6465% | -7.7778% | -1.1494% | -15.493% | -6.5789% | -23.3333% | 7.2727% | -22.7273% | 29.703% | -575% | 71.5033% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.93 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DNTH
2026-06-12 21:09:53
Dianthus Therapeutics (DNTH) shares jumped 8% after reporting positive early data from its late-stage trial of claseprubart for chronic inflammatory demyelinating polyneuropathy (CIDP), with a 75% response rate exceeding expectations. Raymond James reaffirmed its 'Strong Buy' rating and $125 price target, noting the favorable comparison to Sanofi's discontinued competing drug. Dianthus's stock has more than doubled this year, and analysts maintain a strong buy consensus.
2026-06-12 17:09:53
Dianthus Therapeutics (NASDAQ: DNTH) stock is trading higher following positive interim results from its CAPTIVATE Phase 3 trial for claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP). The drug showed a 75% confirmed responder rate and a clean safety profile, alleviating concerns about C1s inhibitors in CIDP. An analyst from William Blair reiterated an Outperform rating, noting that a recent Sanofi trial failure for a competing drug strengthens claseprubart's commercial opportunity.
2026-06-12 11:09:08
Dianthus Therapeutics released an updated corporate presentation highlighting strong clinical data for its autoimmune pipeline, including interim Phase 3 CAPTIVATE trial results for claseprubart in CIDP showing a 75% response rate, exceeding the 50% target. The company also presented positive Phase 2 MaGic trial data for claseprubart in generalized myasthenia gravis, demonstrating statistically significant improvements across multiple endpoints. Dianthus reported a robust financial position with $1.2 billion in cash and investments as of March 31, 2026, providing a runway into 2030 to support ongoing and future clinical developments across its pipeline, including DNTH212 for rheumatology indications.
2026-06-12 11:09:08
Dianthus Therapeutics (DNTH) announced interim responder data from its Phase 3 CAPTIVATE trial for claseprubart in CIDP, showing a 75% response rate among the first 40 patients. The company reported no serious adverse events, leading to a streamlined Part B of the trial. Top-line results for Part B are expected by year-end 2026, with the company maintaining a strong cash position and advancing other development milestones.
2026-06-11 03:09:53
Dianthus Therapeutics (DNTH) stock is experiencing a significant decline, currently down over 9%. This puts the company on track for its largest percentage decrease since January 2025, indicating a notable negative movement in its share price.
2026-06-10 07:36:00
Shares of Dianthus Therapeutics (DNTH) dropped over 20% in premarket trading after Sanofi (SNY) halted a late-stage trial for its experimental therapy, riliprubart, due to efficacy concerns. Riliprubart is comparable to Dianthus's lead asset, claseprubart, which is also a therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). This news suggests potential concerns for Dianthus's own drug development.
